巨噬细胞移动抑制因子蛋白在胰腺癌组织表达的临床意义

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (11): 1301-1303.

巨噬细胞移动抑制因子蛋白在胰腺癌组织表达的临床意义

金志清, 智发朝, 陈学清, 王亚东

南方医科大学南方医院全军消化研究所, 广东, 广州, 510515

出版日期:2004-11-20 发布日期:2004-11-20
基金资助:
收稿日期:2004-4-19。
作者简介:金志清(1965- ),女,第一军医大学硕士研究生,E-mail:potatoneimeng@163.com
通讯作者:智发朝(1962- ),男,副教授,硕士生导师,主要研究领域为胆胰疾病,南方医院全军消化病研究所,电话:020-6l64658

Expression of macrophage migration inhibition factor in pancreatic carcinoma tissue

JIN Zhi-qing, ZHI Fa-chao, CHEN Xue-qing, WANG Ya-dong

南方医科大学南方医院全军消化研究所, 广东, 广州, 510515

Online:2004-11-20 Published:2004-11-20

摘要/Abstract

摘要： 目的观察巨噬细胞移动抑制因子(MIF)在胰腺癌组织中的表达及临床意义。方法应用免疫组织化学技术对36例胰腺癌组织中的MIF蛋白表达进行研究。结果胰腺癌组织中的MIF表达率为69.4%(25/36),高于正常胰腺组织表达率0(0/10)。统计学分析显示,MIF蛋白表达与胰腺癌病理分级呈显著相关(P<0.01),与胰腺癌临床分期及有无局部淋巴结转移间无显著相关(P>0.05)。结论 MIF蛋白表达有可能与胰腺癌的发生有关。

Abstract: Objective To observe the expression of macrophage migration inhibitory factor (MIF) in pancreatic carcinoma tissue and analyze the relationship between MIF expression and clinical manifestations.Methods MIF expression in pancreatic carcinoma and normal pancreatic tissue were detected with immunohistochemical method.Results The positivity rates of MIF in pancreatic carcinoma and normal pancreatic tissue were 69.4%(25/36) and 0(0/10) respectively. MIF expression was found to relate to the degree of cell differentiation of pancreatic carcinoma, but not to the clinical stages or the status of lymph node metastasis.Conclusion MIF might be related to the pathogenesis of pancreatic carcinoma.

中图分类号:

R322.4

金志清, 智发朝, 陈学清, 王亚东. 巨噬细胞移动抑制因子蛋白在胰腺癌组织表达的临床意义[J]. 南方医科大学学报, 2004, 24(11): 1301-1303.

JIN Zhi-qing, ZHI Fa-chao, CHEN Xue-qing, WANG Ya-dong. Expression of macrophage migration inhibition factor in pancreatic carcinoma tissue[J]. Journal of Southern Medical University, 2004, 24(11): 1301-1303.

参考文献

[1] 石玉生,徐素俊,郑小康,等.局部晚期胰腺癌三维适形放射治疗疗效观察[J].第一军医大学学报2004,24(2):213-5.Shi YS, Xu SJ, Zheng XK, et al. Therapeutic effect of threedimensional conformal radiotherapy on locally advanced pancreatic carcinoma [J]. J First Mil Med Univ/Di Yi JunYi Da Xue Xue Bao, 2004, 24(2):213-5.
[2] 周国雄,李兆申,许国铭,等.胰腺癌组织DPC4/Smad mRNA表达的临床意义[J].胰腺病学2002,2(1):25-7.Zhou GX, LI ZS, Xu GM, et al. The expression of DPC4/Smad mRNA in pancreatic carcinoma[J]. Chin J Pancreatol, 2002, 2(1):25-7.
[3] Kamimura A, Kamachi M, Nishihira J, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung [J]. Cancer,2000, 89(2):334-41.
[4] 邹衍泰,李朝龙.胆管结石合并胰腺癌两例报道[J].第一军医大学学报,1997,14,301.Zhou YT, Li CL. Two cases report on pancreatic tumour companyed by gall-stone[J]. J First Mil Med Univ/Di Yi JunYi Da Xue Xue Bao, 1997, 14, 301.
[5] Shimizu T, Abe R, Nakamura H, et al. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis [J]. Biochem Biophys Res Commun, 1999, 264(3):751-8,
[6] Robert Kleemann, Angelika Hausser, Georg Geiger, Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jabl [J].Nature, 2000, 408(6809):211-6
[7] Kato Y, Nakata K, Omagari K, et al. Risk ofhepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses[J]. Cancer, 1994, 74(8):2234-8.
[8] Roskams T, Moshage H, Vos R De, et al. Heparan sulfate proteoglycan expression in normal human liver[J]. Hepatology, 1995, 21(4):950-8.
[9] Calandra T, Bernhagen J, Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor[J]. J ExpMed, 1994, 179:1895-1902.
[10] Bacher M, Christine N, Metz CN, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activationPNAS[J]. Immunol, 1995,154:3863-70.
[11] Takahashi N, Nishihira J, Sato Y, et al. Involvement of macrophage migration inhibitory factor in the mechanism of tumor cell growth[J]. Mol Med, 1998, 4:707-14.